Trial Information | Country | Duration | Sample (%) | Mean Age (Years) | Median Radiation Dose (Gy) | Outcome | |
---|---|---|---|---|---|---|---|
Female | Male | ||||||
Boivin 1982, [19] Retrospective study | USA | 33.0 years | 44.2 | 55.8 | < 44 | > 30 | CV mortality |
Galper 2011, [2] Retrospective study | USA | 14.7 years | 53.6 | 46.4 | 47 | > 36 | CAD (MI, CABG, PTCA), arrhythmias (AICD), valvular disease, pericardial disease |
Giancolo 2010, [20] Prospective study | Italy | 5.0 months | 46.4 | 53.6 | 47.8 +/− 17.4 | 41.2+/−15.6 | CIMT |
Hahn 2017, [21] Retrospective study | Canada | One time analysis | 39.2 | 60.8 | 34.2 | 25 | Ischemic CVD |
Heidenreich 2007, [22] Prospective study | USA | One time analysis | 45.4 | 54.6 | 42 | > 35 | Asymptomatic CAD stress testing, followed by coronary angiography if positive stress test |
Hoppe 1997, [23] Prospective study | USA | 35.0 years | 41.0 | 59.0 | NA | > 30 | Cardiac heart disease (pericarditis, coronary artery disease, functional valvular/conduction defects) |
Hull 2003, [10] Retrospective study | USA | 11.2 years | 39.0 | 61.0 | 25 | 33 | CAD (MI, CABG, PCI, > 75% stenosis) |
Schellong 2010, [24] Prospective study | Germany, Austria | 29.4 years | 41.7 | 58.3 | 27.9 | > 30 | Cardiac heart disease (pericarditis, coronary artery disease, functional valvular/conduction defects) |
Swerdlow 2007, [25] Prospective study | UK | 25.0 years | 38.1 | 61.9 | 34 | > 30 | CVD mortality |
Tsai 2011, [26] Prospective study | Norway | 20.0–24.0 years | 77.5 | 22.5 | 51 +/− 9 | 41 | LV wall motion and EF, and CAD |